NASDAQ
4.77USD
-0.06 (-1.24%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
154M
P/E
—
EPS
—
Beta
1.82
52W range
2.33-8.51
Day range
4.75–4.90
Open
4.84
Prev close
4.83
Volume
73.3K
Avg volume
318.4K
Dividend
0.00
IPO
2015-12-30
https://www.marketbeat.com/instant-alerts/oncocyte-q2-earnings-call-highlights-2026-08-10/ · 8/11/2026+0.20
https://www.globenewswire.com/news-release/2026/03/26/3263407/0/en/IMDX-Submits-GraftAssureDx-for-FDA-Review-and-Reports-Q4-2025-Results.html · 3/26/2026+1.00
https://www.defenseworld.net/2026/03/07/financial-comparison-anbio-biotechnology-nasdaqnnnn-and-oncocyte-nasdaqimdx.html · 3/7/2026+0.00
https://www.defenseworld.net/2026/02/16/anbio-biotechnology-nasdaqnnnn-vs-oncocyte-nasdaqimdx-head-to-head-review.html · 2/16/2026+0.00
https://www.defenseworld.net/2026/02/16/contrasting-anbio-biotechnology-nasdaqnnnn-and-oncocyte-nasdaqimdx.html · 2/16/2026+0.00
https://www.defenseworld.net/2026/02/14/head-to-head-comparison-oncocyte-nasdaqimdx-and-anbio-biotechnology-nasdaqnnnn-2.html · 2/14/2026+0.00
https://www.defenseworld.net/2026/02/08/critical-analysis-oncocyte-nasdaqimdx-versus-anbio-biotechnology-nasdaqnnnn.html · 2/8/2026+0.00
https://www.globenewswire.com/news-release/2026/01/13/3217843/0/en/IMDX-Supports-AST-and-ASHI-STAR-Working-Group-s-Call-for-Decentralized-Transplant-Monitoring.html · 1/13/2026+0.80
https://www.globenewswire.com/news-release/2025/09/24/3155346/0/en/Insight-Molecular-Diagnostics-to-Showcase-Leadership-in-Kidney-Transplant-Management-at-Conferences-in-Singapore-and-Orlando.html · 9/24/2025+0.80
https://prismmediawire.com/imdx-cfo-andrea-james-featured-in-empowered-patient-podcast-on-democratizing-molecular-diagnostics/ · 8/25/2025+0.60
OncoCyte Corporation functions as a molecular diagnostics firm specializing in the research, development, and market introduction of distinctive, laboratory-developed tests aimed at cancer identification. Its operations span both the United States and international territories. The company's key offerings include DetermaRx, a molecular diagnostic tool tailored for detecting early-stage adenocarcinoma of the lung, and DetermaIO, a proprietary gene expression analysis. Additionally, OncoCyte provides a range of expert services, such as biomarker discovery, assay design and refinement, and clinical trial assistance, which encompass offering various biomarker tests to pharmaceutical partners. A strategic partnership with Life Technologies Corporation focuses on the collaborative development and commercialization of the Oncomine Comprehensive Assay Plus and Determa IO assay, intended for integration with the Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was founded in 2009 and maintains its principal office in Irvine, California.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
